Global Sales Revenue Analysis of GSK’s Key Drugs (2000–2025)

On April 1, 2020, GlaxoSmithKline (GSK) completed the sale of Horlicks and its consumer health nutrition businesses in India and other countries to Unilever. GSK merged its Indian consumer health business with Hindustan Unilever, retaining a 5.7% equity stake in the newly listed combined entity. On July 18, 2022, GSK demerged its consumer health division, which was spun off as Haleon plc and separately listed. On July 1, 2022, GSK completed its acquisition of Sierra Oncology, Inc., focusing primarily on developing therapies for rare forms of cancer. Its key asset, momelotinib, is indicated for treating anemia in patients with myelofibrosis. On February 14, 2024, GSK completed its acquisition of Aiolos Bio, Inc., acquiring AIO-001—a potential long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody. On July 3, 2024, GSK announced an updated collaboration agreement with CureVac N.V. to jointly develop mRNA vaccines. In 2024, GSK partnered with Hansoh Pharma to co-develop B7-H3-targeting antibody-drug conjugates HS-20093 and HS-20089. On October 29, 2024, GSK entered into an agreement with Chimagen Biosciences Co., Ltd. (Chengdu) to acquire CMG1A46—a T-cell-mediated antibody simultaneously targeting CD3, CD19, and CD20—for B-cell-driven autoimmune diseases. GSK’s Key Developments in 2025 Financial Performance: In 2025, GSK achieved total revenue of £32.667 billion, representing a 4.11% year-on-year increase. Revenue from innovative medicines amounted to £23.51 billion, up 5.72% year-on-year. Vaccine revenue totaled £9.157 billion, up 0.21% year-on-year.

GSK in 2025: Shingles Vaccine Recovery and Upcoming Regulatory Submission of Hepatitis B ASO Therapy

▎Armstrong On February 4, 2026, GSK released its 2025 financial results, reporting full-year revenue of £32.7 billion, a 7% increase year-on-year. Vaccine business revenue grew by 2%, with the shingles vaccine up 8% and the RSV vaccine up 2%. The shingles vaccine has begun recovering: in the U.S. market—where penetration has already reached 44%—the mature market is entering a contraction phase due to saturation; in Europe, sales rose 42% year-on-year, driven notably by rapid uptake in France; in Japan, expanded insurance coverage led to a 13% weekly increase; and in China, sales also posted growth compared to 2024. Bepirovirsen, GSK’s antisense oligonucleotide (ASO) therapy for hepatitis B, offers functionally curative outcomes for HBV patients and is expected to file for regulatory approval in China during Q1 this year. The RSV vaccine is also expected to file for regulatory approval in China in the first half of this year. Summary GSK has discontinued development of its 24-valent pneumococcal conjugate vaccine and instead continues advancing its >30-valent pneumococcal conjugate vaccine, currently in Phase I clinical trials. Recently, Vaxcyte initiated Phase III clinical trials for its 31-valent pneumococcal conjugate vaccine. Armstrong Technology Deep-Dive Series ・ Comprehensive Review of the GPRC5D Target; ・ Comprehensive Review of the CD40 Target; ・ Comprehensive Review of the CD47 Target; ・ Comprehensive Review of Complement-Targeting Therapeutics; ・ Complement-Targeting Drugs: A Key Direction for Ophthalmic Therapies; ・ Comprehensive Review of the Claudin 6 Target; ・ Comprehensive Review of the Claudin 18.2 Target; ・ Target Landscape: Hot and Cold—The Industry Knows; ・ Landscape of Large-Molecule Drug Development in China; ・ The Criticized 'Me-Too' Strategy; ・ A Century of Adjuvant Development; ・ Insulin: A Century-Long Legacy; ・ CUSBEA: Forty Years Through Storm and Calm; ・ Anxiety in China’s New Drug Development; ・ R&D Competition Among Chinese Biopharmaceutical Companies; ・ Competitive Landscape of Bispecific Antibodies in China; ・ Competitive Landscape of ADCs in China; ・ Comprehensive Review of Bispecific Antibody Technologies in China; ・ Comprehensive Review of ADC Technologies in China; ・ Comprehensive Review of Ambrx Technologies; ・ Comprehensive Review of Vir Biotech Technologies; ・ Comprehensive Review of Immune-Onc Technologies; ・ Comprehensive Review of Gracell Biotechnologies; ・ Comprehensive Review of Zentera Pharmaceuticals; ・ Comprehensive Review of CARsgen Therapeutics; ・ Comprehensive Review of Kactus Bio; ・ Comprehensive Review of Concord Biotech; ・ Comprehensive Review of BeiGene; ・ Comprehensive Review of BeiGene (2nd Edition); ・ Comprehensive Review of Innovent Biologics; ・ Comprehensive Review of Innovent Biologics (2nd Edition); ・ Comprehensive Review of Akeso, Inc.; ・ Comprehensive Review of Henlius Biotech; ・ Comprehensive Review of Simcere Pharmaceutical; ・ Comprehensive Review of Junshi Biosciences; ・ Comprehensive Review of Genor Biopharma; ・ Comprehensive Review of Zhitao Biotech; ・ Comprehensive Review of Daolong Biotech; ・ Comprehensive Review of Shangjian Biotech; ・ Comprehensive Review of KangJen Therapeutics; ・ Comprehensive Review of ESSA Pharma; ・ Comprehensive Review of China Antibody; ・ Comprehensive Review of Akeso, Inc.; ・ Comprehensive Review of Akeso, Inc. (2.0); ・ Comprehensive Review of Harbour BioMed; ・ Comprehensive Review of荣昌生物 (RemeGen); ・ Comprehensive Review of Zai Lab; ・ Comprehensive Review of WuXi Biologics; ・ Comprehensive Review of Hengrui Medicine; ・ Comprehensive Review of Hansoh Pharma; ・ Comprehensive Review of CSPC Pharmaceutical Group; ・ Comprehensive Review of Jiangsu Hengrui Medicine Co., Ltd. (Antibody Drugs); ・ Comprehensive Review of Qilu Pharmaceutical (Antibody Drugs); ・ Comprehensive Review of CSPC Pharmaceutical Group (Antibody Drugs); ・ Comprehensive Review of Hansoh Pharma (Antibody Drugs); ・ Comprehensive Review of Huahai Pharmaceutical (Antibody Drugs); ・ Comprehensive Review of Kelun Pharmaceuticals (Antibody Drugs); ・ Comprehensive Review of Bio-Thera Solutions; ・ Comprehensive Review of Fanenshi Biotech.

GSK Tops Third-Quarter Estimates as New Medicines Drive Growth, Maintains Outlook

5 days ago

GSK exceeded Q3 sales and profit expectations driven by strong demand for new medicines, maintaining annual targets while boosting R&D investment ahead of patent expiries.

reuters

2026-07-08

Alector and GSK End Partnership Following Dementia, Alzheimer's Drug Failures

2026-10-28

GSK Tops Third-Quarter Estimates as New Medicines Drive Growth, Maintains Outlook

2026-10-28

GSK shares dive as weaker vaccine sales unnerve investors

GSK Tops Third-Quarter Estimates as New Medicines Drive Growth, Maintains Outlook

FAQ